level. The fundamental problem is that a profession such as pharmacy by education and by training is more comfortable with scientifically controlled studies. I can relate to this doctrine. My initial research training was in pharmacology, where sample size, random selection, and presence of a control are sine qua non for determining the validity of a study. I found Hepler's treatment of the basic differences between evaluative research and program evaluation to be quite helpful in clarifying pharmacists' concern with the subject.' The point I would like to emphasize is that our study was not so loosely structured as to qualify as internal program evaluation. On the other hand, for reasons more obvious to the very limited number of pharmacy researchers concerned with the issue of economic justification, this study could not be labeled as evaluative research. As we have indicated in the study, we asked that two interventions be reported per day from each clinical pharmacist, taking into account time constraints and to encourage participation. Unlike scientifically controlled studies, which are supposed to be valid and reliable, economic justification studies should have a third very important feature: feasibility. Obviously, it is much more advantageous to report all pharmacists' interventions, but it simply is not economically feasible.
As for the notion of showing your best, we could not rule out.the idea. We lived with the limitation of calculating annual savings as if the pharmacists were delivering only 1.64 interventions per day. This evaluation study was more of a nuisance to the clinical pharmacists than the "show and tell" notion. These pharmacists believe in what they are doing and in their worth. They are so comfortable in their role in patient care that this documentation study probably seemed somewhat irrelevant. We had slow days in which few reports or reports of minimal substance were submitted. I find it difficult to believe that pharmacists do not accept the fact that their intervention can raise the level of patient care to acceptable standards. If this were not the tenet for clinical pharmacy services, we all should pack our bags and go home. Moreover, if the study results were biased, then the number of significant interventions (i.e., those that prevent major complications or save lives) should have constituted the majority of interventions reported and not merely the 3.6 percent that was calculated.
In raising the issue that the amount of saving per reported intervention was higher than that if all interventions were reported, it is presumed that the clinical pharmacists, before reporting their "best intervention," picked up their calculators, calculated the savings of each intervention, and then reported those showing the most savings. If this were the case, then cost-savings calculation has become a primer in clinical pharmacy services. However, this is not the case. Quality of care was and still is the issue of most concern to clinical pharmacists. If you doubt this statement, please read the study. We did report that interventions with impact on quality of care outnumbered those with impact on cost savings by a margin of two to one.
McNamara and Coley also were concerned that the Hawthorne effect triggered the need for the pharmacists to intervene in patient care more during the study period than on a routine basis. This simply is not true. For the Hawthorne effect to occur, a clinical program as well established as ours would actually operate without input from the pharmacists until the practitioners were informed of the necessity to intervene in order to document the worth of their services. At that point, they suddenly would have to become familiar with the physicians, participate in rounds, and begin to intervene in therapy. The physicians, with no questions asked, would then accept their interventions. As for the issue of motivation, I believe that all of our pharmacists are highly motivated; however, the motivation to practice clinical pharmacy and the motivation to report interventions are not the same and should not be equated.
The periods of data collection were chosen to meet our deadline for the study and were average work days. The issue of specialty would be important if we had been evaluating one clinical pharmacy service on a specialized patient care unit. The fact that we evaluated the provision of comprehensive pharmacy services makes this point irrelevant as well as the concern that some pharmacists did more than others.
I was disappointed in the assessment of McNamara and Coley of cost avoidance as being entirely theoretical and as yet untested as a method of determining cost savings. It is true that the term is not widely used. Our use of cost avoidance rather than cost savings is due to the acknowledgment that not all pharmacist savings will lead to net savings; rather, it will lead to better utilization of hospital resources, i.e., cost avoidance. The fact that we used cost avoidance should lend more strength to the study, not make it invalid. Raising this question leads me to believe that pharmacists individually and collectively should start to better understand accounting terms and health care economics in order to survive in today's health care environment.
The authors also misinterpreted the meaning of the non-followed interventions. The term means that physicians did not accept and implement pharmacist interventions, not that the interventions required multiple follow-up. The notion of performing economic justification through scientifically controlled studies is an ambitious undertaking, albeit impossible. These studies, unlike those of clinical research, cannot be controlled. Instead, you aim to minimize the bias. In this regard, the chances of finding two hospitals identical except for the provision of clinical pharmacy services are but nil. Herfindal et al. won the ASHP award for best research article of the year for their attempt to control their economic justification study. However, many observers were not sure that the control site these authors used did in fact fit the description of a true control.' McNamara and Coley raise the issue of the bias of the peer reviewers. Outside peer review is important if you believe that peer reviewers might be hesitant to pass negative judgment on their colleagues. What is neglected are the issues of professional integrity and critical appraisal of one's colleagues, traits that are abundant in our institution's pharmacists. Program evaluation researchers in pharmacy are quick to point out how critical pharmacists are of themselves and of other pharmacists. Our hospital's administrators reacted positively to the study. With that, I believe this study fulfilled its prime objective.
In closing, I would like to leave the readers with a comment made by a noted statistician on the reality of the level of analysis for some types of data. It seems quite applicable to the available methods for cost justification.
